You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》中金料內地第二季新冠疫苗接種率有望續升 關注國企藥企估值修復機會
阿思達克 04-19 14:29
中金發表報告表示,國家醫保局於4月14日發布報告,3月底前已經通過疫苗採購機構向疫苗生產企業預付超240億元人民幣,以保障新冠疫苗免費接種;認為政府進一步鼓勵國內人群接種及疫苗生產企業產能的提升,預計第二季度新冠疫苗接種率有望持續提升。

該行指,人工關節類耗材全國集採開始,仿製藥集採有望進一步推進,相信有助於醫藥行業相關國企價值有望回升,建議關注國企藥企估值修復機會,在海外藥股中,該行看好藥明生物(02269.HK)、阿里健康(00241.HK)、信達生物(01801.HK)、康方生物(09926.HK)、啟明醫療(02500.HK)、海吉亞醫療(06078.HK)及威高股份(01066.HK)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account